Sino Biopharmaceutical's TQ-A3334 Clears Hepatitis B Surface Antigen in 20.8% of High-Dose Patients in Phase II Trial

• Sino Biopharmaceutical presented Phase II results for hepatitis B drug TQ-A3334 at the 2026 American Association for the Study of Liver Diseases meeting.
• The highest dose reduced hepatitis B surface antigen levels when combined with standard antiviral therapy; some patients achieved antigen clearance.
• Lower doses showed no significant antigen reduction; patients with lower baseline antigen levels benefited more from the highest dose.
• Safety was manageable, though serious treatment-related reactions occurred; no deaths or drug-related serious adverse events were reported.
• China's National Medical Products Administration granted TQ-A3334 breakthrough therapy designation in October 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261109-12404904), on November 09, 2026, and is solely responsible for the information contained therein.